Cancer remains a major health issue worldwide. Treatment of local disease has advanced significantly, but systemic, metastasized disease remains an important challenge.
About
ElmediX
Timeline
2015
2015
ElmediX was founded in 2015 in Haasrode
2017
2017
Start minipig (Aachener) study trial in 2017
2018
2018
Additional office in Mechelen opened in 2018
2018
2018
Start dog study trial phase I in 2018
2020
2020
First-In-Human Study Approval Ethical Committee University Hospital of Antwerp (UZA) in June 2020
2020
2020
Approval Federal Agency for Medicines and Health Products (FAMHP) in July 2020
2020
2020
Start First-In-Human clinical trial in October 2020
We strive for the highest possible reliability and quality of our products. Our wish is to be recognized as “best-in-class” for the delivery of high-quality innovative products which we offer to our partners as a commercial opportunity. We aspire a good long-term strategic collaboration with all our partners.
We intend to make a reasonable profit from our business activities, so that we can meet our commitments, continue our growth and achieve our goals.
Our mission encourages us to contribute to human well-being and to our community, which also includes environment friendly measures. We strive to develop products that have a minimal impact on the environment in terms of design, raw materials, production, packaging, recycling and waste disposal.
Our Values
Strong values define our corporate culture and help us fulfill ElmediX’ mission and vision.
Reliability
As a company, we want to represent a stable, caring and reliable partner for all our stakeholders: patients, healthcare providers and hospitals, suppliers, employees and shareholders.
Integrity
We strive to take our responsibilities as a company with a high sense of citizenship. It promotes respect, fairness, transparency and justice with which we lead our professional practices and determines our positive contribution to society.
Teamwork
As a team, we work constructively together on the same goal in an open positive atmosphere, with respect for each other, striving for a pleasant, motivating and inspiring working environment.
Engagement
Commitment, taking responsibility, initiative and continuous improvement are deeply embedded in our corporate culture.
Management Team
John-Paul Bogers (CEO) is Professor in Histology and Cell Biology at the University of Antwerp. He is also the founder or board member of 6 Belgian and foreign (South-Africa) companies (all medical or technology driven).
John-Paul was principle investigator of three large clinical trials on molecular biomarkers, successfully applied for 20 national, industry-funded and international projects (of which 3 EU funded programs). He was promotor of 13 defended PhD students and published > 150 scientific papers.
Johan Van den Bossche (CTO) is a serial entrepreneur. He co-founded Krypton Electronic Engineering and managed the company until its sale in 2005 to Metris (today NIKON Metrology). Since then, he has been involved in several new ventures: LAB Motion Systems (Air bearings), Vesalius Medical Technologies (Bursitis treatment), Xenomatix (Lidar for autonomous driving), Faromatics (Robotics & AI for farm automation, Barcelona), Saint start-up (Start-up Data Analytics, Athens) and Mauhn (AGI).
Johan graduated from KUL as Electrotechnical engineer and worked on a PhD in robotics at PMA, Leuven and NIST, Washington DC.
Oleg Rudenko (CMO) studied Electrotechnical Engineering at the Technical University Delft and Medicine at the University of Antwerp.
Oleg worked in anesthesiology at Antwerp University Hospital.
Oleg was Clinical research physician at SGS until he started at ElmediX.
Rosanna Finotto is an experienced Management Assistant who has worked in large companies (Douwe Egberts, Grontmij, Puratos, Cheops Technology) over the last 30 years.
Rosanna joined ElmediX in January 2019 in an assisting role to the Management Team.
Finance professional with +25 years of experience in national and international companies, with strong skills in financial accounting, reporting, as well as budget management and business administration.
As a hands-on and achievement oriented person, her focus is on implementing, improving and supporting a functional finance reporting and analysis system, in alignment with the goals and mission of the company.
Carine joined ElmediX in December 2019.
Advisory Board
Professor Ahmad Awada was born in Lebanon and studied Medicine at the Université Libre de Bruxelles (ULB), Belgium. He specialised in Internal Medicine and Medical Oncology at Jules Bordet Institute, in Brussels, until 1992. During his specialisation, he also followed trainings in the clinical development of new anticancer drugs. As a research fellow, he stayed in the Netherlands (New Drug Development Office, Free University, Amsterdam) and in San Antonio, USA (Institute for Drug Development). He focused on the clinical development of new anticancer agents from cytotoxic and endocrine agents to molecular-targeted agents and more recently immunotherapies.
Back from the USA at the beginning of 1994, Dr Awada became Assistant Head of Medical Oncology Clinic, and Head of the New Drugs Development Unit at Jules Bordet Institute, Brussels. Since April 2005, he is the Head of the Medical Oncology Clinic. In addition, and from 1st March 2011, Dr Awada was held Associate Head of Medicine Department. More recently, on 7th July 2017, Dr Awada was appointed Head of Oncology Medicine Department. He has an important clinical activity in the treatment of solid tumors and in particular breast cancer. Dr Awada took an active part in the development of new drugs in several solid tumors, some of them already widely used. Dr. Awada is membership of several international scientific societies (ASCO, EORTC, ESMO), cofounder of Oncodistinct network for oncology research and Professor of Clinical Medicine and Medical Oncology at the Université Libre de Bruxelles.
Dr Awada is author or co-author of 32 book chapters and, 330 articles in international publications.
Dr. Susan Bates received her M.D. degree from the University of Arkansas School of Medicine. She completed her clinical training in internal medicine at Georgetown University in Washington D.C., and in medical oncology at the National Cancer Institute (NCI) in Bethesda. MD Dr. Bates was a Lead Clinical Investigator and Head of the Molecular Therapeutics Section in the Developmental Therapeutics Branch of the Center for Cancer Research before moving to Columbia University in August 2015.
Mark W. Dewhirst, DVM, PhD, FASTRO, FAAAS is the Emeritus Gustavo S. Montana Professor of Radiation Oncology, former Associate Dean for Faculty Mentoring and Vice Director for Basic Science in the Duke Cancer Institute. Dr. Dewhirst has research interests in tumor hypoxia, angiogenesis, hyperthermia and drug transport and had NIH funding to study these subjects for more than 30 years. He has >600 peer-reviewed publications, book chapters and reviews. His works have been cited more than 40,000 times in the literature. He has given named lectures at the University of Western Ontario, Thomas Jefferson University, Stanford University, the Norwegian Radium Hospital in Oslo, The University of Pennsylvania and the New Zealand Cancer Society. He received the Alumni of the Year Award from Colorado State University College of Veterinary Medicine. He received the Failla Medal from the Radiation Research Society in 2008, the Eugene Robinson award for excellence hyperthermia research in 1992 and a similar award from the European Society for Hyperthermic Oncology in 2009. He received the Gold Medal Award from the American Society for Radiation Oncology in 2012. He is also a Fellow of the American Association for the Advancement of Science. He is a Senior Editor of Cancer Research and Editor-in-Chief of the International Journal of Hyperthermia. He graduated from the University of Arizona in 1971 with a degree in Chemistry and Colorado State University in 1975 and 1979 with DVM and PhD degrees, respectively.
Zeljko Vujaskovic, MD, PhD, is a physician/scientist and professor who heads the Division of Translational Radiation Sciences in the Department of Radiation Oncology at the University of Maryland School of Medicine (UMSOM) in Baltimore. For more than 30 years, his career has been defined by transdisciplinary research that bridges the gap between basic science and clinical research to ultimately improve outcomes and long-term quality of life among cancer patients.
From 1999 to 2012 Dr. Vujaskovic served as a clinical radiation oncologist and director of the Normal Tissue Injury Laboratory at Duke University, where he was an associate professor of Radiation Oncology, Pathology, and Medical Physics. At Duke he also directed the Clinical Hyperthermia Program and served as associate director of the General Clinical Research Center. His laboratory focused on elucidating mechanisms underlying radiation injury and radiation therapy-induced toxicities in normal tissue. With his laboratory members, he published a series of seminal articles on tissue hypoxia and radiation exposure.
Dr. Vujaskovic has published more than 150 articles and book chapters on radiation therapy, radiation injury, and hyperthermia topics. He has directed national and international research collaborations and is an active participant in cooperative group trials.
In 2016 he was honored with the Society for Thermal Medicine’s J. Eugene Robinson Award, given each year to an investigator who has made outstanding contributions to hyperthermic oncology.
Director of Pancreatic Cancer Center of Shanghai Jiaotong University, Oncology Department Director of Renji Hospital, Chairman of MDT Expert Committee of Renji Hospital.
Chairman of Pancreatic Cancer Expert Committee of Chinese Society of Clinical Oncology, Committee of Oncology Branch of Chinese Medical Association and Group Leader of Pancreatic Oncology, Vice Chairman of the Pancreatic Disease Professional Committee of the Chinese Research Hospital Association.
Presided over the first “Chinese Expert Consensus on the Diagnosis and Treatment of Pancreatic Cancer” and the first “CSCO Guidelines for Pancreatic Cancer Diagnosis and Treatment” of the Chinese Society of Clinical Oncology.
The associate editor of “Journal of Pancreatology”, the editorial board member of “Cancer Research”, “JHO”, “Tumor”, “Clinical Oncology” and other journals.
Published more than 100 SCI papers with more than 1,000 times citation.
Studied medicine in Amsterdam and Leiden and achieved her Ph.D. (subject Whole Body Hyperthermia) at the Erasmus University in Rotterdam in 1987. Is since 1978 engaged in clinical research on hyperthermia in addition to radiotherapy or chemotherapy at the Erasmus MC Cancer Institute. Is (co)author of >130 peer-reviewed publications on several types of hyperthermia (whole body, local, loco-regional, interstitial, and perfusion). Was president of the European Society for Hyperthermic Oncology from 1996 to 1999. Is winner of several awards among which the Lund Science Award (1994), the ESHO-BSD Award (1999), and the Eugene Robinson Award. Was appointed Knight in the Order of Orange-Nassau by the Queen of the Netherlands in 2010 for her contributions in the field of hyperthermia.
Prof. Jaak Ph. Janssens is doctor honoris causa in personalized oncology and molecular biology. As President of the European Cancer Prevention and Editor of the “European Journal of Cancer Prevention”, he leads an international team of cancer experts in various studies, especially breast cancer. His work has been published in over 200 scientific articles and books.
Dr. ir. Alex Van den Bossche has done research work in medical implantable devices in the framework of his doctoral thesis on the "Automatic Implantable Defibrillator". He co-founded Krypton NV, a KU Leuven high-tech spin-off company specialising in industrial optical metrology. He served as managing director for 15 years until the successful trade sale of the company to Metris/Nikon. He co-founded Allegro Investment Fund, specialising in technology-based early stage Private Equity. Since 5 years he acquired GrindoSonic, a KULeuven spin-off specialising in measurement systems for material characterisation and Quality Control where he serves as CEO.
Our Team
Since its inception in 2015, ElmediX has brought together a highly skilled team. In the (near) future, our team will be expanded with other enthusiastic colleagues. Interested in joining the team? See our current vacancies.
